HK Stock Market Move | SKB BIO(06990) rose nearly 3% in the closing trading session, with three research results selected for oral presentation at the 2026 ASCO Annual Meeting.

15:26 24/04/2026

Colenbo Biotech (06990) rose nearly 3% in the last session, as of the time of writing, up 2.24% to HK$475, with a turnover of HK$235 million.

SKB BIO (06990) rose nearly 3% at the close, with a 2.24% increase at the time of writing, trading at HK$475 with a trading volume of HK$235 million. On the news front, the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 will be held in Chicago, USA from May 29 to June 2. According to SKB BIO's official announcement, the company will be presenting the results of three clinical studies on TROP2 ADC sacituzumab govitecan (sac-TMT, Jyseleca), the next-generation selective RET inhibitor repotrectinib (A400/EP0031, Pranlorin), and the new ADC SKB500 at this conference. The full research abstracts will be released on the ASCO official website on May 21, 2026, local time.

CHINARES PHARMA(03320): China Resources Double-Crane Pharmaceutical net profit in the first quarter was 501 million yuan, a decrease of 4.085% year-on-year.

CHINARES PHARMA (03320): Dong-E-Jiao's net profit in the first quarter was 4.55 billion yuan, a year-on-year increase of 7.12%.

GREAT EAGLE H (00041) issued 48,000 shares due to the exercise of stock options.

CHINARES PHARMA(03320): China Resources Double-Crane Pharmaceutical net profit in the first quarter was 501 million yuan, a decrease of 4.085% year-on-year.

CHINARES PHARMA (03320): Dong-E-Jiao's net profit in the first quarter was 4.55 billion yuan, a year-on-year increase of 7.12%.

GREAT EAGLE H (00041) issued 48,000 shares due to the exercise of stock options.